Highlight
• Zimislecel is an innovative stem cell-derived, fully differentiated islet cell therapy for type 1 diabetes that aims to restore physiologic insulin production.
• A phase 1-2 clinical trial demonstrated successful engraftment, islet function evidenced by C-peptide production, insulin independence in 83% of participants, and freedom from severe hypoglycemic events.
• Glucocorticoid-free immunosuppression was used to reduce adverse effects, with neutropenia as the most common serious adverse event.
• Despite a small sample size and short follow-up, these outcomes recommend further research into zimislecel’s therapeutic potential.
